Navigation Links
Advanced Life Sciences Announces Third Quarter 2009 Financial Results
Date:11/10/2009

data in anthrax and plague and receiving orphan designation in tularemia and plague."

Dr. Flavin added: "As another indication of the government's interest in Restanza as a biodefense agent, the Company was invited to submit a full proposal in response to a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services for the advanced development of Restanza as a broad spectrum countermeasure for biodefense. BARDA funding could significantly help to advance Restanza toward approval by the FDA as an important medical countermeasure, and toward consideration by the government for acquisition and stockpiling."

Operating Expense Analysis

  • Research and development expenses were $0.9 million for the three months ended September 30, 2009 compared to $11.2 million for the three months ended September 30, 2008. This difference was primarily due to the $10.0 million milestone expense incurred under our license agreement with Abbott in the third quarter of 2008.
  • Selling, general and administrative expenses totaled $2.2 million for the three months ended September 30, 2009 compared to $1.8 million for the same period in 2008.

Third Quarter Events

  • Reported results from a pivotal primate study in which Restanza demonstrated efficacy in treating anthrax infection;
  • Announced results showing Restanza's protective efficacy in a plague pivotal primate study;
  • Received FDA Orphan Drug Designation for Restanza in plague and tularemia;
  • Received complete response letter from FDA for Restanza in CAP.

Business Goals for 2009

  • Complete studies under the Department of Defense (DoD) contract and report data from pivotal primate study measuring Restanza's protective efficacy in tularemia;
  • Attend December 9th FDA Anti-Infective
    '/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boston Scientifics Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
2. Free 2D/3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging
3. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
4. Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System
5. Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA
6. Advanced Health Media Named to Deloittes 2009 Technology Fast 500(TM)
7. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
8. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
9. FDA Approves New Treatment for Advanced Form of Kidney Cancer
10. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
11. New ALS Patient Simulator Advanced Provides Valuable Training for EMS Teams and In-Hospital Emergency Personnel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... YORK , Sept. 16, 2014 The ... Foundation (HNF) announced today an agreement to collaborate on ... and support the development of a stronger CMT patient ... financial support to several HNF,s initiatives including: ... in the HNF website featuring  HNF newsletters, materials and ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare and ... Finland , have begun to ... ODM-201, an investigational oral androgen receptor inhibitor in ... in men with castration-resistant prostate cancer who have ... detectable metastases. The trial is designed to determine ...
(Date:9/15/2014)... , Sept. 15, 2014 /CNW/ - Health Minister Rona ... will make available for donation over $2.5 million in personal ... aid in the global response to the Ebola outbreak in ... WHO reported a shortage of equipment in the affected countries ... by front-line workers in the affected countries. ...
Breaking Medicine Technology:Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3
... 28 Having hypertension, or high blood,pressure, reduces blood ... to a new study presented today at the annual ... "While hypertension is not a cause of Alzheimer,s disease, ... brain that increases its vulnerability,to the effects of the ...
... to ... total knee replacement, MINNEAPOLIS, ... of OrthoGlide Medial Knee Implant initial,clinical data., Data representing ... was presented on November 10th, 2007 at the,American College of ...
Cached Medicine Technology:High Blood Pressure May Heighten Effects of Alzheimer's Disease 2Clinical Data Presented on OrthoGlide(R) Medial Knee Implant 2
(Date:9/15/2014)... Club wear is provocative, revealing, or fetish ... with a very relaxed dress code. There are various types ... on the location of the club, the club's dress code ... and retailer, has delightedly pronounced its new series of delicate ... low prices. , A nightclub (also known as a discothèque, ...
(Date:9/15/2014)... 2014 1Heart Caregiver Services Training ... staff of Regency Park Oak Knoll during the ... Executive Director Gladys Broxton. This continuing professional education ... 1Heart Shirley Billedo and Regency Park officers of ... Jeanine Hernandez and Activities Coordinator Alfonso Escalante. , ...
(Date:9/15/2014)... BROOK, Ill. (PRWEB) September 15, 2014 ... at risk for stroke who might benefit from aggressive ... in the journal Radiology. , The study looked ... of the major blood vessels supplying blood to the ... stenosis is the primary cause of up to 20 ...
(Date:9/15/2014)... neuroscience researchers at the University of Copenhagen have ... cause Parkinson,s disease. The findings have recently been ... . , The defining symptoms of Parkinson,s ... There is currently no cure for the condition, ... with the potential to shed some light on ...
(Date:9/15/2014)... 15, 2014 Today, Zane Benefits, the ... Bank’s Speaking on Business radio show. , According ... so employers know it doesn’t make sense to choose ... also save the employer and employee as much as ... of Zions Bank's Speaking on Business , Chris ...
Breaking Medicine News(10 mins):Health News:Delicate Club Wears Are For Sale At Fecbek.com 2Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 2Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 3Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 4Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Researchers debunk myth about Parkinson's disease 2Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2
... Oregon Health & Science University,s Vaccine and Gene Therapy Institute ... of infection before it becomes a rapidly replicating, ... the spread of the disease. The research is published in ... and will appear in a future printed edition. ...
... Bob Woodruff was injured while reporting in Iraq in 2006, ... his ability to recall and produce common words a ... language skills thanks to intensive behavioral therapy reading and ... for patients with aphasia has always been and will always ...
... Martek Biosciences Corporation (Nasdaq: MATK ) announced ... quarter of fiscal 2009 on March 4, 2009, at approximately ... 4:45 p.m. ET Martek will conduct a conference call to ... listen to the call live via webcast by visiting Martek,s ...
... but not available in U.S., was stopped early due ... -- A large study of tibolone, a drug used ... halted early after researchers found that the synthetic steroid ... survivors of the disease. , Tibolone isn,t available in ...
... Patient Check-In Company(TM), the leader in patient-intake, announced ... bringing total investment to date to $25 million. ... fund of the BlueCross BlueShield Association, and Sandbox ... Venture Partners, HLM Venture Partners, and Long River ...
... pathway that is responsible for generating excess connective tissue ... human patients with scleroderma. The study, published by Cell ... Developmental Cell , also reveals an intriguing but unexpected ... disease. , Platelet derived growth factors (PDGF) regulate ...
Cached Medicine News:Health News:OHSU vaccine research targets HIV in the slower, early stage of infection 2Health News:Exploring new pathways to language 2Health News:Menopause Drug Tied to Breast Cancer Recurrence 2Health News:Phreesia Secures $11.6M Series C Funding Led by BlueCross BlueShield Venture Partners and Sandbox Industries 2Health News:Phreesia Secures $11.6M Series C Funding Led by BlueCross BlueShield Venture Partners and Sandbox Industries 3Health News:Phreesia Secures $11.6M Series C Funding Led by BlueCross BlueShield Venture Partners and Sandbox Industries 4Health News:Tumor suppressor may attenuate fibrotic disease 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: